Patients with a history of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, therapy-related AML, or AML with MDS-related cytogenetics were eligible to enroll in the trial, Lancet explains.

Results of the study showed that there was a 3.5-month improvement in overall survival associated with CPX-351, he says. Additionally, CPX-351 led to a 31% reduction in the risk of death. These findings are very encouraging as it shows a benefit with an agent that is not the standard of care.

Patients with a history of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, therapy-related AML, or AML with MDS-related cytogenetics were eligible to enroll in the trial, Lancet explains.

Results of the study showed that there was a 3.5-month improvement in overall survival associated with CPX-351, he says. Additionally, CPX-351 led to a 31% reduction in the risk of death. These findings are very encouraging as it shows a benefit with an agent that is not the standard of care.